Immiticide

Verify with FDA CVM →

61 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
61
Total Reports
1
Deaths Reported
160.0%
Death Rate

Active Ingredients

Immiticide

Administration Routes

IntramuscularUnknownSubcutaneousOral

Species Affected

Dog 61

Most Affected Breeds

Retriever - Labrador 5
Shepherd Dog - German 5
Beagle 4
Terrier - Bull - American Pit 4
Dog (unknown) 4
Dachshund (unspecified) 3
Pointing Dog - German Short-haired 3
Crossbred Canine/dog 3
Hound (unspecified) 2
Boxer (German Boxer) 2

Most Reported Reactions

Lack of efficacy (endoparasite) - heartworm 48
Intentional misuse 7
Medication error NOS 5
Other abnormal test result NOS 2
Diarrhoea 2
Emesis 2
Seizure NOS 2
Abnormal cytology 2
INEFFECTIVE, HEARTWORM MICROFI 2
Pruritus 1
Skin lesion NOS 1
Heart murmur 1

Outcome Breakdown

Ongoing
47 (77.0%)
Outcome Unknown
10 (16.4%)
Recovered/Normal
3 (4.9%)
Euthanized
1 (1.6%)

Data Summary

Metric Value
Total adverse event reports 61
Reports involving death 1
Case-fatality rate (reported events) 160.0%
Distinct species in reports 1
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Immiticide Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 61 adverse event reports referencing Immiticide, including 1 reports in which the animal died — a 160.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Immiticide. Reported administration routes include Intramuscular, Unknown, Subcutaneous, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Immiticide reports are Dog (61 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (5), Shepherd Dog - German (5), Beagle (4) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Immiticide are Lack of efficacy (endoparasite) - heartworm (48), Intentional misuse (7), Medication error NOS (5), Other abnormal test result NOS (2). Of the 61 reports with a coded outcome, Ongoing is the leading category at 77.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Immiticide.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial